Search

Your search keyword '"Benoit Brethon"' showing total 6 results
Start Over Author "Benoit Brethon" Publisher springer science and business media llc
6 results on '"Benoit Brethon"'

2. Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study

Author

Franco Locatelli, Gerhard Zugmaier, Noemi Mergen, Peter Bader, Sima Jeha, Paul-Gerhardt Schlegel, Jean-Pierre Bourquin, Rupert Handgretinger, Benoit Brethon, Claudia Rossig, Christiane Chen-Santel, University of Zurich, and Zugmaier, Gerhard

Subjects
Oncology, 10036 Medical Clinic, 2720 Hematology, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 610 Medicine & health, 2730 Oncology, Hematology, RC254-282
Published
2021
Full Text
View/download PDF

3. Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study

Author

Sima Jeha, Rupert Handgretinger, Paul G. Schlegel, Benoit Brethon, Jean-Pierre Bourquin, Claudia Rossig, Christiane Chen-Santel, Peter Bader, Franco Locatelli, Noemi Mergen, Gerhard Zugmaier, University of Zurich, and Zugmaier, Gerhard

Subjects
Oncology, medicine.medical_specialty, Cancer therapy, Lymphoblastic Leukemia, 2720 Hematology, MEDLINE, 610 Medicine & health, lcsh:RC254-282, Internal medicine, Correspondence, medicine, Author Correction, Cancer, business.industry, Expanded Access Study, Hematology, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, 10036 Medical Clinic, Relapsed refractory, BLINATUMOMAB, 2730 Oncology, Blinatumomab, business, medicine.drug
Published
2020
Full Text
View/download PDF

4. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment

Author

Benoit Brethon, A von Stackelberg, Francesco Locatelli, Ondrej Hrusak, Lia Gore, Tanya M. Trippett, G. Zugmaier, Ester Mejstrikova, Michael J. Borowitz, and James A. Whitlock

Subjects
Male, Adolescent, Lymphoblastic Leukemia, Antigens, CD19, Antineoplastic Agents, lcsh:RC254-282, resistance, 03 medical and health sciences, 0302 clinical medicine, Text mining, Antigen, blinatumomab, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, expression, Correspondence, Antibodies, Bispecific, Biomarkers, Tumor, medicine, Humans, Child, B cell, therapy, biology, business.industry, Infant, Hematology, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.anatomical_structure, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, Oncology, Child, Preschool, 030220 oncology & carcinogenesis, Cancer research, biology.protein, Female, Blinatumomab, Neoplasm Recurrence, Local, CD19 Negative, Antibody, business, Tumor immunology, 030215 immunology, medicine.drug
Published
2017
Full Text
View/download PDF

5. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)

Author

S. de Botton, Xavier Thomas, Bruno Quesnel, Hugues Leroy, Thierry Leblanc, Claude Preudhomme, Anne Auvrignon, N Boissel, Olivier Hermine, Emmanuel Raffoux, Benoit Brethon, André Baruchel, Hervé Dombret, Guy Leverger, and Nathalie Philippe

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Adolescent, Population, Gene mutation, Biology, medicine.disease_cause, Bioinformatics, Proto-Oncogene Proteins p21(ras), hemic and lymphatic diseases, Internal medicine, medicine, Humans, Child, education, Core binding factor acute myeloid leukemia, Aged, Retrospective Studies, Mutation, education.field_of_study, Hematology, Core Binding Factors, Infant, Myeloid leukemia, Exons, Middle Aged, Prognosis, medicine.disease, Survival Rate, Proto-Oncogene Proteins c-kit, Leukemia, Haematopoiesis, fms-Like Tyrosine Kinase 3, Oncology, Leukemia, Myeloid, Child, Preschool, Acute Disease, Cancer research, Female
Abstract

In core binding factors (CBF) acute myeloid leukemia (AML), the disruption of CBFalpha/beta genes impairs normal hematopoietic differentiation and is supposed to cooperate with additional mutations promoting proliferation. The incidence and the prognosis of receptor tyrosine kinase (RTK) c-Kit and FLT3 mutations and Ras mutations were evaluated in 103 pediatric and adult patients with CBF-AML. c-Kit mutations were present in 17% patients. c-Kit exon 8 mutations were more frequent in inv(16) than in t(8;21) subset (20 versus 6%). Only one patient had FLT3-ITD but FLT3-D835 was as frequent as reported in AML population (7%). Ras mutations were significantly more frequent in inv(16) than in t(8;21) subset (36 versus 8%, P=0.001). RTK mutations were associated with a higher white blood cell count (WBC) (36 versus 21 G/L, P=0.05). FLT3 mutations were significantly associated with a shorter EFS and survival (P

Published
2006
Full Text
View/download PDF

6. Late effects in survivors of infantile acute leukemia: a study of the L.E.A program

Author

Pierre G. Lutz, Justyna Kanold, G. Michel, D Plantaz, J.-H. Dalle, S. Ducassou, Julie Berbis, Claire Oudin, S Thouvenin, Guy Leverger, Jacinthe Bonneau, Marilyne Poirée, P Chastagner, Pascal Auquier, Benoit Brethon, M.-D. Tabone, Virginie Gandemer, N Sirvent, Yves Bertrand, Z Hamidou, André Baruchel, CHU Pontchaillou [Rennes], Service de pédiatrie, d'hématologie et d'oncologie [Hôpital de La Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Institut d'hématologie et d'oncologie pédiatrique [CHU - HCL] (IHOPe), Hospices Civils de Lyon (HCL), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Bordeaux [Bordeaux], Service d'Oncologie Pédiatrique [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Unité d'Hémato-Immunologie pédiatrique [Hôpital Robert Debré, Paris], Service d'Immuno-hématologie pédiatrique [Hôpital Robert Debré, Paris], Hôpital Robert Debré-Hôpital Robert Debré, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre Hospitalier Universitaire de Nice (CHU Nice), CHU Grenoble, Centre d'Investigation Clinique [CHU Clermont-Ferrand] (CIC 1405), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, CHU Clermont-Ferrand, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Strasbourg, Service d'hématologie-immunologie-oncologie pédiatrique [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and CHU Saint-Etienne

Subjects
Male, medicine.medical_specialty, [SDV.CAN]Life Sciences [q-bio]/Cancer, Antineoplastic Agents, Fusion gene, 03 medical and health sciences, 0302 clinical medicine, Cancer Survivors, Internal medicine, medicine, Humans, Letter to the Editor, ComputingMilieux_MISCELLANEOUS, Acute leukemia, Hematology, business.industry, Hematopoietic Stem Cell Transplantation, Infant, Newborn, Infant, Precursor Cell Lymphoblastic Leukemia-Lymphoma, medicine.disease, 3. Good health, Lymphoma, Leukemia, Myeloid, Acute, Haematopoiesis, Leukemia, Oncology, Apoptosis, 030220 oncology & carcinogenesis, Immunology, Quality of Life, Cancer research, Female, Stem cell, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, 030215 immunology
Abstract

International audience

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results